CUSIP: 68234L207
Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
7,412,499
-
Share change
-
-6,276,578
-
Total reported value
-
$10,374,000
-
Price per share
-
$1.40
-
Number of holders
-
30
-
Value change
-
-$8,776,344
-
Number of buys
-
10
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 68234L207?
CUSIP 68234L207 identifies ONCS - ONCOSEC MED INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2018
-
Previous quarter:
Q2 2018
Recent filing periods for CUSIP 68234L207:
Institutional Holders of ONCOSEC MED INC - COM NEW (ONCS) as of Q3 2018
As of 30 Sep 2018,
ONCOSEC MED INC - COM NEW (ONCS) was held by
30 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,412,499 shares.
The largest 10 holders included
Vanguard Group Inc, Point72 Asset Management, L.P., NEXTHERA CAPITAL LP, venBio Select Advisor LLC, 683 Capital Management, LLC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, PRICE T ROWE ASSOCIATES INC /MD/, DRW Securities, LLC, and DEUTSCHE BANK AG\.
This page lists
30
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.